• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Lisata Therapeutics

Monday, June 03, 2024
CP
Oncology
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.
Lisata Therapeutics
Company Website: https://www.lisata.com/
Lead Product in Development: LSTA1

Exchange

Nasdaq

Ticker

LSTA

Company HQ City

Basking Ridge

Company HQ State

New Jersey

Company HQ Country

United States

CEO/Top Company Official

David J. Mazzo, PhD, President and CEO

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS